Cryoport, Inc. (NASDAQ: CYRX)

Cryoport, Inc. is a leading global provider of integrated, temperature-controlled supply chain solutions tailored for the life sciences industry, with a strong focus on the rapidly expanding cell and gene therapy market. The company specializes in ensuring the safe, compliant storage, handling, and delivery of high-value, temperature-sensitive biological materials, including cell and gene therapies, immunotherapies, and other critical biologics. Cryoport supports the entire lifecycle of these therapies, from preclinical research through clinical trials to global commercialization, by offering end-to-end solutions that maintain product viability, identity, and quality. Its proprietary Chain of Compliance framework integrates chain-of-custody, chain-of-condition, and chain-of-identity protocols, addressing the complex regulatory and logistical demands of modern biopharmaceutical development.

Cryoport generates revenue through a combination of specialized services and products designed for the life sciences sector. Its primary offerings include advanced temperature-controlled logistics, biostorage, kitting and labeling, clinical sample management, cryopreservation services, and cryogenic systems manufacturing. The company serves a diverse customer base, including biopharmaceutical and pharmaceutical companies, animal health markets, reproductive medicine providers, academic institutions, and government agencies. Revenue is derived from service contracts, equipment sales, and long-term storage solutions, with a significant portion tied to the growing demand for cell and gene therapy support.

The company operates through the following segments.

• Life Sciences Services: This segment delivers integrated temperature-controlled supply chain solutions, including BioLogistics, BioStorage, BioServices, and Cryopreservation services. BioLogistics provides specialized transportation for cell and gene therapies, ensuring compliance with stringent regulatory standards. BioStorage offers long-term storage for preclinical and early-stage clinical materials, while BioServices includes kitting, labeling, and fulfillment for clinical and commercial workflows. Cryopreservation services, branded as IntegriCell, standardize the preservation of cellular starting materials to reduce variability in therapy development. These solutions are underpinned by the Cryoportal digital logistics platform, which integrates data analytics, real-time monitoring, and automation to enhance operational efficiency and regulatory compliance.

• Life Sciences Products: This segment focuses on the design and manufacturing of cryogenic systems, including freezers, dewars, and transport systems used for the storage and movement of biological materials. Products such as MVE Series Freezers, High-Efficiency Series, and Vapor Shipper Series cater to biorepositories, clinical laboratories, and biopharmaceutical companies. The segment also develops connected platforms like the MVE CryoVerse Ecosystem, which provides real-time monitoring and cloud-based visibility for stored materials. These systems are critical for maintaining the integrity of temperature-sensitive biologics across global supply chains.

Cryoport holds a distinctive position in the life sciences supply chain industry, particularly within the cell and gene therapy market. Its competitive advantages stem from its proprietary technologies, including the Cryoportal platform and Chain of Compliance framework, which provide end-to-end visibility, traceability, and regulatory adherence. The company is the first globally to achieve ISO 21973:2020 certification for cell therapy transportation, reinforcing its leadership in compliance and quality. While Cryoport faces competition from specialty couriers like World Courier, UPS Healthcare, and Biocair, its integrated solutions and deep expertise in cell and gene therapies set it apart. In cryogenic systems manufacturing, competitors include Azenta Life Sciences and Phase 2, but Cryoport’s FDA-registered facilities and advanced product portfolio provide a strong market foothold. The company’s strategic partnerships, such as its collaboration with DHL, further enhance its global reach and service differentiation.

Cryoport’s customer base primarily consists of biotechnology and pharmaceutical companies, contract research organizations, contract development and manufacturing organizations, central laboratories, fertility clinics, animal health companies, and academic institutions. In 2025, the company supported 760 clinical trials and 20 commercially approved cell and gene therapies, reflecting its critical role in the development and commercialization of advanced therapies. While the filing does not disclose specific customer names, Cryoport’s solutions are integral to organizations requiring precise temperature control and regulatory compliance for high-value biological materials. Its global footprint spans the Americas, Europe, the Middle East, Africa, and Asia-Pacific, with the majority of revenue originating from the Americas.